Best in Biotech 25 Feb 2025 Seven biotech spinouts to watch out for in 2025 …Therapeutics Disease area: neurology Target area: central nervous system Total funding: $250 million As central nervous system (CNS) diseases typically originate in specific cell types, most current treatments target receptors… February 25, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 21 Oct 2016 New Partnership comes to the Rescue in Neurological Diseases …Central Nervous System (CNS). Although no more details are given, it will likely target epilepsy and Parkinson’s, for which it already has drugs in clinical development. Figure 1. UCB’s neurology… October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2022 bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases …This expands bit.bio’s central nervous system (CNS) portfolio to four disease models and three cell types. bit.bio’s cell products are reprogrammed from human induced pluripotent stem cells (hiPSCs) using the… November 30, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Oct 2024 Six biotech companies advancing multiple sclerosis therapies Multiple sclerosis is a chronic disease of the central nervous system (CNS). As an unpredictable disease that affects people differently, some patients with multiple sclerosis may only have mild symptoms,… October 24, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2017 Austrian Researchers Identify Target for Treatment of Multiple Sclerosis Multiple sclerosis is the most common disease of the CNS in young adults. Researchers may have stumbled across a new approach for its treatment. Researchers at the Medical University of… October 19, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 15 Feb 2024 Turning the tide: recent advancements in childhood cancer research …new transgenes that offer a more targeted approach, and minimize the risk of neurotoxicities. “Developing therapies that are tailored specifically for pediatric patients will generate better medicines to address CNS… February 15, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 May 2024 10 notable pharma and biotech venture capital arms …Biotherapeutics, which is creating a new class of targeted gene therapies for both central nervous system (CNS) and non-CNS disorders, Umoja Biopharma, which is pioneering the future of immunotherapy by… May 23, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2023 Report: China leads the way with phase 1 studies …I trials across the top therapeutic areas. Oncology, infectious disease, CNS, cardiovascular and metabolic disorders are the top therapeutic areas for phase I trials across the top Asian locations of… February 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Oct 2023 Five impactful biotech companies to know in New York …New York looking to make the most of this opportunity. Table of contents Axsome Therapeutics With a focus on CNS conditions that have currently limited treatment options, Axsome Therapeutics is… October 3, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Nov 2022 The five hottest biotech startup companies in Brazil …that was launched last year. The company aims to develop a viral therapy for childhood cancers in the central nervous system (CNS). CNS cancers are very challenging to treat as… November 10, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 1 Dec 2025 Stem cell therapy’s avant-garde: Eight companies leading the way …an emerging player in regenerative neurology, building on a decade of expertise in producing high-purity neurons and glia from human iPSCs. Originally focused on supplying subtype-specific human central nervous system (CNS) cells for research… December 1, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 3 Sep 2018 Oxford Biotech Raises €40M to Deliver Drugs to Hard-to-Reach Targets …central nervous system (CNS), as well as metabolic diseases. Led by the former CSO of Ablynx, a biotech that was acquired by Sanofi for €3.9Bn earlier this year, Evox… September 3, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email